NCT02140320View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

AsthmaHealthy Volunteers

Interventions

DRUG

RV1729 single dose

Safety and tolerability of single dose

DRUG

RV1729 matching placebo single dose

Safety and tolerability of single dose

DRUG

RV1729 14 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 matching placebo 14 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 28 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 matching placebo 28 day repeat dose

Safety and tolerability of repeat doses

Trial Locations (2)

NW10 7EW

London

M23 9QZ

Manchester

All Listed Sponsors

lead

Respivert Ltd

INDUSTRY

NCT02140320 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days | Biotech Hunter | Biotech Hunter